Dorsey Wright & Associates Buys 6,832 Shares of Abivax SA Sponsored ADR $ABVX

Dorsey Wright & Associates boosted its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 41.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,452 shares of the company’s stock after acquiring an additional 6,832 shares during the quarter. Dorsey Wright & Associates’ holdings in Abivax were worth $2,611,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. GHP Investment Advisors Inc. increased its holdings in Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares in the last quarter. Bank of America Corp DE raised its holdings in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after buying an additional 344 shares during the period. WPG Advisers LLC lifted its stake in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Abivax in the fourth quarter valued at about $61,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ABVX. Truist Financial lifted their price target on shares of Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and upped their price target for the stock from $108.00 to $158.00 in a research report on Tuesday, June 30th. Finally, Morgan Stanley dropped their price objective on Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 2nd. Fourteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $148.54.

Abivax Stock Down 0.8%

Shares of Abivax stock opened at $136.65 on Friday. The stock has a market capitalization of $10.90 billion, a price-to-earnings ratio of -26.23 and a beta of 0.87. The company has a 50-day simple moving average of $116.97 and a two-hundred day simple moving average of $118.47. Abivax SA Sponsored ADR has a twelve month low of $9.86 and a twelve month high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts anticipate that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.